AbbVie Inc (ABBV)vsOpko Health Inc (OPK)
ABBV
AbbVie Inc
$227.23
+1.32%
HEALTHCARE · Cap: $380.57B
OPK
Opko Health Inc
$1.44
-1.37%
HEALTHCARE · Cap: $1.06B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 10710% more annual revenue ($62.82B vs $581.12M). ABBV leads profitability with a 5.8% profit margin vs -36.6%. ABBV appears more attractively valued with a PEG of 0.59. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
OPK
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-55.6%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Intrinsic value data unavailable for OPK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Reasonable price relative to book value
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
ROE of -17.7% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.59 suggests the stock is reasonably priced for its growth.
Bull Case : OPK
The strongest argument for OPK centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 105.1x leaves little room for execution misses.
Bear Case : OPK
The primary concerns for OPK are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
ABBV profiles as a value stock while OPK is a turnaround play — different risk/reward profiles.
OPK carries more volatility with a beta of 1.41 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Opko Health Inc
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
OPKO Health, Inc., a healthcare company, is engaged in the pharmaceutical and diagnostic businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company is headquartered in Miami, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?